Erytech Pharma (NASDAQ: ERYP) is one of 106 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Erytech Pharma to related companies based on the strength of its dividends, analyst recommendations, risk, valuation, profitability, earnings and institutional ownership.
Earnings and Valuation
This table compares Erytech Pharma and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Erytech Pharma||N/A||-$37.89 million||-2.32|
|Erytech Pharma Competitors||$1.02 billion||$93.10 million||-4.69|
Insider and Institutional Ownership
25.7% of Erytech Pharma shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.3% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Erytech Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Erytech Pharma Competitors||-8,316.86%||-75.40%||-24.08%|
This is a breakdown of recent recommendations for Erytech Pharma and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Erytech Pharma Competitors||641||2219||5389||219||2.61|
Erytech Pharma presently has a consensus price target of $43.00, suggesting a potential upside of 457.72%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.98%. Given Erytech Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe Erytech Pharma is more favorable than its peers.
Erytech Pharma beats its peers on 7 of the 12 factors compared.
About Erytech Pharma
ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.